Patents by Inventor Benjamin Gerald Tehan

Benjamin Gerald Tehan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Bicyclic aza compounds as muscarinic Mand/or Mreceptor agonists
    Patent number: 11945801
    Abstract: This invention relates to compounds that are agonists of the muscarinic M1 and/or M4 receptor and which are useful in the treatment of diseases mediated by the muscarinic M1 and M4 receptors. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula where X1; X2; R1 and R4 are as defined herein.
    Type: Grant
    Filed: December 9, 2019
    Date of Patent: April 2, 2024
    Assignees: Heptares Therapeutics Limited, Allergan Pharmaceuticals International Limited
    Inventors: Giles Albert Brown, Barry John Teobald, Benjamin Gerald Tehan
  • 4-(3-CYANOPHENYL)-6-PYRIDINYLPYRIMIDINE MGLU5 MODULATORS
    Publication number: 20240092754
    Abstract: The disclosures herein relate to novel compounds of formula wherein R1, R2, R3 and R4 and n are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of inflammation, neurological or psychiatric disorders associated with modulating mGlu5 receptor function.
    Type: Application
    Filed: March 24, 2023
    Publication date: March 21, 2024
    Inventors: John Andrew CHRISTOPHER, Miles Stuart CONGREVE, Sarah Joanne AVES, Benjamin Gerald TEHAN
  • Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists
    Patent number: 11834407
    Abstract: This invention relates to compounds that are agonists of the muscarinic M1 receptor or M1 and M4 receptors and which are useful in the treatment of muscarinic M1 or M1/M4 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula wherein Q4, Q5, R5, p, V, Q1, Q2, X1, X2 and W are defined herein.
    Type: Grant
    Filed: May 3, 2021
    Date of Patent: December 5, 2023
    Assignee: Heptares Therapeutics Limited
    Inventors: Giles Albert Brown, Miles Stuart Congreve, Mark Pickworth, Benjamin Gerald Tehan
  • Muscarinic M1 receptor agonists
    Patent number: 11793817
    Abstract: This invention relates to compounds that are agonists of the muscarinic M1 receptor and which are useful in the treatment of muscarinic M1 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula I, where n is 1 or 2; p is 0, 1 or 2; q is 0, 1 or 2; and R1-R6 are as defined herein.
    Type: Grant
    Filed: April 9, 2021
    Date of Patent: October 24, 2023
    Assignee: Heptares Therapeutics Limited
    Inventors: Miles Stuart Congreve, Giles Albert Brown, Julie Elaine Cansfield, Benjamin Gerald Tehan
  • Pharmaceutical compounds
    Patent number: 11773090
    Abstract: This invention relates to compounds that are agonists of the muscarinic M1 and/or M4 receptor and which are useful in the treatment of diseases mediated by the muscarinic M1 and M4 receptors. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula where Y, R1, R2 and R4 are as defined herein.
    Type: Grant
    Filed: September 17, 2020
    Date of Patent: October 3, 2023
    Assignee: Heptares Therapeutics Limited
    Inventors: Giles Albert Brown, Barry John Teobald, Benjamin Gerald Tehan
  • Methods of treatment using 4-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 modulators
    Patent number: 11680053
    Abstract: The disclosures herein relate to novel compounds of formula wherein R1, R2, R3 and R4 and n are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of inflammation, neurological or psychiatric disorders associated with modulating mGlu5 receptor function.
    Type: Grant
    Filed: November 4, 2021
    Date of Patent: June 20, 2023
    Assignee: Heptares Therapeutics Limited
    Inventors: John Andrew Christopher, Miles Stuart Congreve, Sarah Joanne Aves, Benjamin Gerald Tehan
  • Methods of treatment using 4-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 modulators
    Patent number: 11584732
    Abstract: The disclosures herein relate to novel compounds of formula wherein R1, R2, R3 and R4 and n are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of inflammation, neurological or psychiatric disorders associated with modulating mGlu5 receptor function.
    Type: Grant
    Filed: March 16, 2021
    Date of Patent: February 21, 2023
    Assignee: Heptares Therapeutics Limited
    Inventors: John Andrew Christopher, Miles Stuart Congreve, Sarah Joanne Aves, Benjamin Gerald Tehan
  • MUSCARINIC AGONISTS
    Publication number: 20230002354
    Abstract: This invention relates to compounds that are agonists of the muscarinic M1 receptor and/or M4 receptor and which are useful in the treatment of muscarinic M1/M4 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds include those according to formula 1 or a salt thereof, wherein q, r, s, Q, R1, R2?, R2?, R3 and R4 are as defined herein.
    Type: Application
    Filed: February 15, 2022
    Publication date: January 5, 2023
    Inventors: Giles Albert Brown, Julie Cansfield, Mark Pickworth, Benjamin Gerald Tehan, Barry John Teobald
  • OXIME COMPOUNDS AS AGONISTS OF THE MUSCARINIC M1 AND/OR M4 RECEPTOR
    Publication number: 20220298133
    Abstract: This invention relates to compounds that are agonists of the muscarinic M1 and/or M4 receptor and which are useful in the treatment of diseases mediated by the muscarinic M1 and M4 receptors. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula (I) where p; q; X 1; Y; R1; R2; R3; R4; R5 and R6 are as defined herein.
    Type: Application
    Filed: December 15, 2021
    Publication date: September 22, 2022
    Inventors: Giles Albert Brown, Benjamin Gerald Tehan
  • SUBSTITUTED CYCLOHEXANES AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR AGONISTS
    Publication number: 20220213034
    Abstract: This invention relates to compounds that are agonists of the muscarinic M1 receptor or M1 and M4 receptors and which are useful in the treatment of muscarinic M1 or M1/M4 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula wherein Q4, Q5, R5, p, V, Q1, Q2, X1, X2 and W are defined herein.
    Type: Application
    Filed: May 3, 2021
    Publication date: July 7, 2022
    Inventors: Giles Albert Brown, Miles Stuart Congreve, Mark Pickworth, Benjamin Gerald Tehan
  • Pharmaceutical compounds
    Patent number: 11352342
    Abstract: This invention relates to compounds that are agonists of the muscarinic M1 and/or M4 receptor and which are useful in the treatment of diseases mediated by the muscarinic M1 and M4 receptors. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula (1) wherein X1; X2; R1 and R4 are as defined herein.
    Type: Grant
    Filed: August 21, 2020
    Date of Patent: June 7, 2022
    Assignee: Heptares Therapeutics Limited
    Inventors: Giles Albert Brown, Julie Elaine Cansfield, Miles Stuart Congreve, Benjamin Gerald Tehan, Barry John Teobald
  • Muscarinic agonists
    Patent number: 11324738
    Abstract: This invention relates to compounds that are agonists of the muscarinic M1 receptor and/or M4 receptor and which are useful in the treatment of muscarinic M1/M4 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds include those according to formula 1a or a salt thereof, wherein n, p, Q, R1, R2, R3, R9 and R4 are as defined herein.
    Type: Grant
    Filed: December 27, 2019
    Date of Patent: May 10, 2022
    Assignee: Heptares Therapeutics Limited
    Inventors: Giles Albert Brown, Miles Stuart Congreve, Mark Pickworth, Mark David Rackham, Benjamin Gerald Tehan
  • Pharmaceutical compounds
    Patent number: 11319312
    Abstract: This invention relates to compounds that are agonists of the muscarinic M1 and/or M4 receptor and which are useful in the treatment of diseases mediated by the muscarinic M1 and M4 receptors. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula where X1; X2; X3; X4; R1 R2 and R4 are as defined herein.
    Type: Grant
    Filed: October 13, 2020
    Date of Patent: May 3, 2022
    Inventors: Giles Albert Brown, Barry John Teobald, Benjamin Gerald Tehan
  • OXEXIN 1 RECEPTOR ANTAGONISTS
    Publication number: 20220098165
    Abstract: The disclosures herein relate to novel compounds of formula (1) and salts thereof, wherein V; W; X; Y; Z; R1; R2; R3; R4 and R5 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of neurological or psychiatric disorders associated with orexin receptors.
    Type: Application
    Filed: January 28, 2020
    Publication date: March 31, 2022
    Inventors: Giles Albert Brown, Miles Stuart Congreve, John Andrew Christopher, Nigel Alan Swain, Sarah Joanne Bucknell, Anne Mary Stephenson, Benjamin Gerald Tehan, Geraint Jones, Mark Mills, Anil Patel, Andrew William Phillips
  • 4-(3-CYANOPHENYL)-6-PYRIDINYLPYRIMIDINE MGLU5 MODULATORS
    Publication number: 20220056009
    Abstract: The disclosures herein relate to novel compounds of formula wherein R1, R2, R3 and R4 and n are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of inflammation, neurological or psychiatric disorders associated with modulating mGlu5 receptor function.
    Type: Application
    Filed: November 4, 2021
    Publication date: February 24, 2022
    Inventors: John Andrew CHRISTOPHER, Miles Stuart CONGREVE, Sarah Joanne AVES, Benjamin Gerald TEHAN
  • Muscarinic agonists
    Patent number: 11254656
    Abstract: This invention relates to compounds that are agonists of the muscarinic M1 receptor and/or M4 receptor and which are useful in the treatment of muscarinic M1/M4 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds include those according to formula 1 or a salt thereof, wherein q, r, s, Q, R1, R2?, R2?, R3 and R4 are as defined herein.
    Type: Grant
    Filed: July 29, 2020
    Date of Patent: February 22, 2022
    Assignee: Heptares Therapeutics Limited
    Inventors: Giles Albert Brown, Julie Elaine Cansfield, Mark Pickworth, Benjamin Gerald Tehan, Barry John Teobald
  • MUSCARINIC RECEPTOR AGONISTS
    Publication number: 20220048928
    Abstract: This invention relates to compounds that are agonists of the muscarinic M1 receptor and which are useful in the treatment of muscarinic M1 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula where m, p, q, W, Z, Y, X1, X2, R1, R2, R3 and R4 are as defined herein.
    Type: Application
    Filed: June 11, 2021
    Publication date: February 17, 2022
    Inventors: Miles Stuart Congreve, Giles Albert Brown, Benjamin Gerald Tehan, Mark Pickworth, Julie Elaine Cansfield
  • OREXIN 1 RECEPTOR ANTAGONISTS
    Publication number: 20220041573
    Abstract: The disclosures herein relate to novel compounds of formula (I): and salts thereof, wherein W; X; Y; Z; R1; R2; R3 and R4 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of neurological or psychiatric disorders associated with orexin receptors.
    Type: Application
    Filed: December 16, 2019
    Publication date: February 10, 2022
    Applicants: Heptares Therapeutics Limited, Heptares Therapeutics Limited
    Inventors: Giles Albert Brown, Miles Stuart Congreve, John Andrew Christopher, Nigel Alan Swain, Sarah Joanne Bucknell, Anne Mary Stephenson, Benjamin Gerald Tehan, Mark Mills, Anil Patel
  • QUINOLINONE AND BENZOXAZINE DERIVATIVES AS MUSCARINIC M1 AND/OR M4 RECEPTOR AGONISTS
    Publication number: 20220017504
    Abstract: This invention related to compounds having activity as muscarinic M1 or M1 and M4 receptor agonists which are useful in the treatment of diseases mediated by the muscarinic M1 and M4 receptors. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula (I) where X1; X2; X3; X4; Y; Z; n, R1 and R2 are defined herein.
    Type: Application
    Filed: December 9, 2019
    Publication date: January 20, 2022
    Inventors: Giles Albert Brown, Miles Stuart Congreve, Benjamin Gerald Tehan, Mark Pickworth
  • Oxime compounds as agonists of the muscarinic M1 and/or M4 receptor
    Patent number: 11208396
    Abstract: This invention relates to compounds that are agonists of the muscarinic M1 and/or M4 receptor and which are useful in the treatment of diseases mediated by the muscarinic M1 and M4 receptors. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula (I) where p; q; X1; X2; Y; R1; R2; R3; R4; R5 and R6 are as defined herein.
    Type: Grant
    Filed: November 2, 2016
    Date of Patent: December 28, 2021
    Assignee: Heptares Therapeutics Limited
    Inventors: Giles Albert Brown, Benjamin Gerald Tehan